Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Bootstrap Analysis of 30-Day Costs
Performance of 1,000 bootstrap replicates indicates an 85.3% probability of cost savings with bivalirudin monotherapy compared with heparin (unfractionated or low molecular weight heparin) with upstream GPI (yellow line) and a 57.4% probability of lower cost with bivalirudin monotherapy compared with heparin (unfractionated or low molecular weight heparin) and catheterization laboratory-initiated GPI (black line). Abbreviations as in Figure 1.
|
